Somnomed Ltd (SOM)
Australian Securities Exchange · Australia · prices in AUD · close of 21 Oct 2026
Key indicators
| Last close | AUD 0.290 |
|---|---|
| 52-week range | 0.230 – 0.945 |
| Return, 1 month / 3 months | −12.1% / −35.6% |
| Return, 1 year / 3 years | −67.0% / −42.0% |
| Trend | Below its 200-day average |
| RSI (14) | 50 |
| Volatility (1 year) | 58.2% |
| Worst drawdown (1 year) | -73.3% |
| Average daily value traded | 0.02M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
SomnoMed is a medical device company based in Sydney, Australia, that makes oral appliances for people with sleep-disordered breathing. Its SomnoDent devices are worn in the mouth during sleep to hold the lower jaw forward and keep the airway open, offering an alternative to other treatments for obstructive sleep apnea. The company works with dentists and sleep specialists and sells its appliances in Australia and in overseas markets including North America and Europe.
Somnomed Ltd trades under the code SOM on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Somnomed Ltd (SOM) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.290 on 21 October 2026.
Its price-based Market X-Ray is 24 out of 100 (a weak price profile), ranking 1,555 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 67.0% and over the last three months it fell 35.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 12 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -44.3% | ||
| From 52-week high | -67.0% | ||
| Momentum | 10 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -35.6% | ||
| 6-month return | -53.2% | ||
| 12-month return, skipping the last month | -62.5% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 58.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -73.3% | ||
| Liquidity | 38 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M AUD | ||
| Zero-volume days | 23.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +7.4% |
|---|---|
| 1 month | −12.1% |
| 3 months | −35.6% |
| 6 months | −53.2% |
| 1 year | −67.0% |
| 3 years | −42.0% |
| 5 years | −88.2% |
Signals
| 50-day / 200-day average | 0.317 / 0.520 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.015 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.